Sentynl completes asset transfer of CUTX-101 Copper Histidinate product candidate for treatment of…
A rolling submission of the CUTX-101 New Drug Application (NDA) to the FDA is ongoing, with expected completion in 2024
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.